Axsome Therapeutics Inc [AXSM] stock is trading at $118.51, up 1.17%. An important factor to consider is whether the stock is rising or falling in short-term value. The AXSM shares have gain 8.51% over the last week, with a monthly amount glided 12.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on June 03, 2025, and set its price target to $185. On April 07, 2025, Jefferies initiated with a Buy rating and assigned a price target of $200 on the stock. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $176 on February 11, 2025. Mizuho reiterated its recommendation of a Outperform and reduced its price target to $122 on December 31, 2024. Wells Fargo started tracking with a Overweight rating for this stock on September 03, 2024, and assigned it a price target of $140. In a note dated August 06, 2024, BofA Securities upgraded a Buy rating on this stock and boosted its target price from $95 to $106.
Axsome Therapeutics Inc [AXSM] stock has fluctuated between $75.56 and $139.13 over the past year. Currently, Wall Street analysts expect the stock to reach $189 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $118.51 at the most recent close of the market. An investor can expect a potential return of 59.48% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 495.03M for the trailing twelve months, which represents a growth of 72.13%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.5%, and Net Profit Margin reading is -0.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -3.58 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 117.23 points at the first support level, and at 115.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 120.15, and for the 2nd resistance point, it is at 121.78.
Ratios To Look Out For
For context, Axsome Therapeutics Inc’s Current Ratio is 1.57. On the other hand, the Quick Ratio is 1.51, and the Cash Ratio is 0.89. Considering the valuation of this stock, the price to sales ratio is 11.95, the price to book ratio is 80.79.
Transactions by insiders
Recent insider trading involved JEFFS ROGER, Director, that happened on Aug 22 ’25 when 16694.0 shares were purchased. General Counsel, Murdock Hunter R. completed a deal on Jun 20 ’25 to sell 7500.0 shares. Meanwhile, General Counsel Murdock Hunter R. sold 6014.0 shares on Jun 23 ’25.
